22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).

      Clinical journal of the American Society of Nephrology : CJASN
      Anemia, drug therapy, etiology, Animals, Arteries, drug effects, physiopathology, Blood Pressure, Chronic Disease, Erythropoietin, adverse effects, Evidence-Based Medicine, Hematinics, Humans, Hypertension, chemically induced, Kidney Diseases, complications, therapy, Peritoneal Dialysis, Continuous Ambulatory, Renal Dialysis, Risk Assessment

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This review summarizes the evidence for a hypertensinogenic effect of Erythropoietin (Epo) in normal human subjects and predialysis, hemodialysis, and continuous ambulatory peritoneal dialysis (CAPD) patients. The possible mechanisms of Epo-induced hypertension are examined with in vivo animal and in vitro data, as well as pathophysiological human studies in both normal subjects and CKD patients. The evidence for a hypertensinogenic effect of erythropoiesis-stimulating agents (ESAs) in normal subjects, predialysis CKD, hemodialysis, and CAPD patients is compelling. Epo increases BP directly and notably independently of its erythropoietic effect and its effect on blood rheology. The potential for the development of future agents that might act as specific stimulators of erythropoiesis, devoid of direct hemodynamic side effects is underscored.

          Related collections

          Author and article information

          Comments

          Comment on this article